Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Eloxx Pharmaceuticals, Inc is a biotechnology business based in the US. Eloxx Pharmaceuticals shares (ELOX) are listed on the NASDAQ and all prices are listed in US Dollars. Eloxx Pharmaceuticals employs 29 staff and has a market cap (total outstanding shares value) of USD$172.3 million.
|Latest market close||USD$2.94|
|52-week range||USD$1.44 - USD$8.1614|
|50-day moving average||USD$3.1438|
|200-day moving average||USD$3.0112|
|Wall St. target price||USD$5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.447|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||-28.81%|
|1 month (2020-12-23)||-34.38%|
|3 months (2020-10-22)||-2.97%|
|6 months (2020-07-22)||-2.00%|
|1 year (2020-01-22)||-37.04%|
|2 years (2019-01-22)||-72.29%|
|3 years (2018-01-22)||8.6|
|5 years (2016-01-22)||1,052.94%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-43.49%|
|Return on equity TTM||-132.93%|
|Market capitalisation||USD$172.3 million|
TTM: trailing 12 months
There are currently 1.4 million Eloxx Pharmaceuticals shares held short by investors – that's known as Eloxx Pharmaceuticals's "short interest". This figure is 0.2% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Eloxx Pharmaceuticals shares can be evaluated.
Eloxx Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Eloxx Pharmaceuticals shares currently shorted divided by the average quantity of Eloxx Pharmaceuticals shares traded daily (recently around 35061.088082902). Eloxx Pharmaceuticals's SIR currently stands at 38.6. In other words for every 100,000 Eloxx Pharmaceuticals shares traded daily on the market, roughly 38600 shares are currently held short.
However Eloxx Pharmaceuticals's short interest can also be evaluated against the total number of Eloxx Pharmaceuticals shares, or, against the total number of tradable Eloxx Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eloxx Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Eloxx Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0479% of the tradable shares (for every 100,000 tradable Eloxx Pharmaceuticals shares, roughly 48 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Eloxx Pharmaceuticals.
Find out more about how you can short Eloxx Pharmaceuticals stock.
We're not expecting Eloxx Pharmaceuticals to pay a dividend over the next 12 months.
Eloxx Pharmaceuticals's shares were split on a 1:20 basis on 20 December 2017. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eloxx Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Eloxx Pharmaceuticals shares which in turn could have impacted Eloxx Pharmaceuticals's share price.
Over the last 12 months, Eloxx Pharmaceuticals's shares have ranged in value from as little as $1.44 up to $8.1614. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eloxx Pharmaceuticals's is 2.4018. This would suggest that Eloxx Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.